The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be reversing from a recent downtrend after hitting highs in October.

Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette Syndrome. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted EU orphan medicinal product designation for the treatment of West Syndrome by the European Commission.

Catalyst Pharmaceutical Partners Inc. (CPRX) Stock Quote and News:

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel.

EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. EnteroMedics’ proprietary technology, VBLOC® vagal blocking therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. VBLOC allows people with obesity to take a positive path towards weight loss, addressing the lifelong challenge of obesity and its comorbidities without sacrificing wellbeing or comfort. EnteroMedics’ Maestro Rechargeable System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.

After hitting highs above $2 in October, the Athersys (NASDAQ: ATHX) chart is back down on a support level around $1.60. A move upward on Wednesday starting turning trend and momentum indicators, dropping hints that the chart could be ready to go through an upswing again off the support point.

Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem(R) cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft versus host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.

Athersys (ATHX) Stock Quote and News:

Three straight days of closing ahead has the AEterna Zentaris chart on watch for continued upward pressure. Shares rose 8.5 percent on Tuesday to close near the high of the day on increased volume, which is a bullish sign as the stock nears resistance. Shares traded as low as $1.75 last week, but have recovered to close on Tuesday at $2.16 on Read More

Although the chart for Nautilus Inc. (NYSE: NLS) fell sharply in July, the stock has still posted solid gains for 2012 and is back on the rise. Resistance is ahead around $3.00, but the chart is showing bullish signs of trend and momentum, indicating that if the resistance is broken, a run at the 52-week high could happen.

Headquartered in Vancouver, Washington, Nautilus, Inc. is a global fitness products company providing innovative, quality solutions to help people achieve a healthy lifestyle. With a brand portfolio including Nautilus®, Bowflex®, TreadClimber®, Schwinn®, Schwinn FitnessTM, Universal® and CoreBody Reformer™, Nautilus markets innovative fitness products through Direct and Retail channels.

Nautilus Group (NLS) Stock Quote and News:

The PositiveID (OTCBB: PSID) stock chart made a new 52-week low yesterday before buying pressure pulled the stock price up to close the day with a hammer/doji candle. A possible reversal candle, the chart is holding support firmly at 3 cents with resistance not coming into play until 4 cents. A long-term positive divergence between the MACD and the PPS has the chart on radar for an overall trend shift. Read More

The CrowdGather (OTCBB: CRWG) chart keeps producing 25 percent bounces off a solid support at 20 cents back up to a resistance at 25 cents. The pps continues to hold over the 200 day simple moving average and is looking towards the 50 dma at 27 cents. The indicators look to be trying to reverse course as the Relative Strength Index is now pushing through the 50 mark, indicating that momentum is entering a bullish mode. Static resistance is ahead at 30 cents. If tested, the climb off support could be indicating a reversal Read More

A look at Anthera Pharmaceuticals’ (NASDAQ: ANTH) 15-minute charts, combined with the daily charts, shows that the stock could be aligning for a “dead cat bounce.” Technical traders will be looking for a new support level to be established and any upward movement to meet resistance near $0.80, where the stock still has a short-term, open gap that is unfilled presently.

The stock has languished Read More

Even though RXI Pharmaceuticals Corp. (OTCBB: RXII) has only been trading for less than two months, the technicals show that a base has formed and that there is potential for a move in the near term as the moving averages have converged and the bollinger bands are tightening. Technical traders will be watching for an increase in volume to hold support at 8 cents and for pressure to try and take out resistance Read More

After a pullback from a recent run that saw the price per share more than double, the Medical Marijuana Inc. (Pink Sheets: MJNA) stock chart is on watch for a bounce. Support is established at 3.5 and 4 cents with resistance in place at 5 and 6 cents. Read More